Published in Clin Immunol on May 21, 2007
Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol (2009) 1.30
Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol (2009) 1.14
Automated indirect immunofluorescence evaluation of antinuclear autoantibodies on HEp-2 cells. Clin Dev Immunol (2012) 1.05
New platform technology for comprehensive serological diagnostics of autoimmune diseases. Clin Dev Immunol (2012) 1.04
Automation in indirect immunofluorescence testing: a new step in the evolution of the autoimmunology laboratory. Auto Immun Highlights (2012) 0.82
How should a district general hospital immunology service screen for anti-nuclear antibodies? An 'in-the-field' audit. Clin Exp Immunol (2015) 0.79
Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. Clin Immunol (2015) 0.78
Evaluation of an automated connective tissue disease screening assay in Korean patients with systemic rheumatic diseases. PLoS One (2017) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96
Presentation of two bone marrow elements; the tart cell and the L.E. cell. Proc Staff Meet Mayo Clin (1948) 1.35
Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum (1997) 1.26
Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol (2004) 1.03
Analysis of human sera that are polyreactive in an addressable laser bead immunoassay. Clin Immunol (2006) 1.01
Comparison of a multiplex, bead-based fluorescent assay and immunofluorescence methods for the detection of ANA and ANCA autoantibodies in human serum. J Immunol Methods (2006) 1.01
Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmunity (2005) 0.99
Methods of choice for diagnostic antinuclear antibody (ANA) screening: benefit of adding antigen-specific assays to immunofluorescence microscopy. J Autoimmun (2004) 0.92
Evaluation of the new multiplexed immunoassay, FIDIS, for simultaneous quantitative determination of antinuclear antibodies and comparison with conventional methods. Am J Clin Pathol (2003) 0.88
Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol (2010) 2.89
Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.08
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 1.76
Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest (2009) 1.75
Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum (2002) 1.62
Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol (2004) 1.54
Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol (2009) 1.52
T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J Immunol (2003) 1.39
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.38
Metabolic control of T cell activation and death in SLE. Autoimmun Rev (2008) 1.28
T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol (2005) 1.27
mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov Med (2010) 1.21
Risk preference following adolescent alcohol use is associated with corrupted encoding of costs but not rewards by mesolimbic dopamine. Proc Natl Acad Sci U S A (2011) 1.19
Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem (2006) 1.16
Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum (2011) 1.13
Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol (2007) 1.08
Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry (2012) 1.08
Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol (2014) 1.03
Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity (2010) 1.02
Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol (2009) 0.99
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol (2013) 0.99
T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J (2012) 0.99
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin Immunol (2008) 0.96
Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor γ. J Immunol (2012) 0.96
Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol (2010) 0.95
Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum (2008) 0.95
T-cell and B-cell signaling biomarkers and treatment targets in lupus. Curr Opin Rheumatol (2009) 0.94
Nitric oxide, mitochondrial hyperpolarization, and T cell activation. Free Radic Biol Med (2007) 0.94
Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity (2008) 0.93
Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin Immunol (2005) 0.93
Adhesion-dependent Skp2 transcription requires selenocysteine tRNA gene transcription-activating factor (STAF). Biochem J (2011) 0.92
Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother (2009) 0.91
Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochem J (2008) 0.91
ZNF143 mediates basal and tissue-specific expression of human transaldolase. J Biol Chem (2003) 0.91
Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antioxid Redox Signal (2014) 0.90
Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol (2013) 0.88
Obesity: effects on cardiovascular disease and its diagnosis. J Am Board Fam Med (2008) 0.88
Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol (2014) 0.87
Detection of lupus anticoagulant and successful anticoagulation in familial Sneddon syndrome. Ann Rheum Dis (2010) 0.87
CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J Immunol (2005) 0.87
CCL genes in multiple sclerosis and systemic lupus erythematosus. J Neuroimmunol (2008) 0.86
Signaling abnormalities in systemic lupus erythematosus as potential drug targets. Endocr Metab Immune Disord Drug Targets (2006) 0.86
Possible pathogenic nature of the recently discovered TT virus: does it play a role in autoimmune rheumatic diseases? Autoimmun Rev (2006) 0.86
Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates. J Thorac Oncol (2009) 0.85
Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol (2010) 0.85
DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus. Autoimmunity (2013) 0.84
Bifunctional, chemically patterned flat stamps for microcontact printing of polar inks. Langmuir (2008) 0.83
Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum (2013) 0.83
Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J Immunol (2010) 0.82
Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS One (2013) 0.82
Self-assembled monolayers of subphthalocyanines on gold substrates. Org Lett (2010) 0.82
Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines. Leuk Res (2009) 0.81
The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus. Clin Immunol (2006) 0.81
Metabolic regulation of organelle homeostasis in lupus T cells. Clin Immunol (2012) 0.81
Coronary artery aneurysm related to percutaneous coronary intervention. Int J Cardiol (2008) 0.80
The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity. Br J Clin Pharmacol (2006) 0.80
Deletion of Ser-171 causes inactivation, proteasome-mediated degradation and complete deficiency of human transaldolase. Biochem J (2004) 0.80
Clinical policy: critical issues in the sedation of pediatric patients in the emergency department. J Emerg Nurs (2008) 0.78
Lymphoedema: a paradoxical effect of tumour necrosis factor inhibitors - case report and review of literature. BMJ Case Rep (2009) 0.77
Clinical policy: Critical issues in the sedation of pediatric patients in the emergency department. Ann Emerg Med (2008) 0.77
Elevation of the tumor marker CA125 in right heart failure. South Med J (2004) 0.77
Differential regulation of hydrogen peroxide and Fas-dependent apoptosis pathways by dehydroascorbate, the oxidized form of vitamin C. Antioxid Redox Signal (2002) 0.77
The role of endocytic recycling in autoimmunity. Methods Mol Biol (2012) 0.76
Metabolic control of the epigenome in systemic Lupus erythematosus. Autoimmunity (2013) 0.76
Overview of signal processing by the immune system in systemic lupus erythematosus. Autoimmun Rev (2008) 0.75
Oxidative stress and endosome recycling are complementary mechanisms reorganizing the T-cell receptor signaling complex in SLE. Clin Immunol (2011) 0.75
Obstructive sleep apnea syndrome: anesthetic concerns. Int Anesthesiol Clin (2012) 0.75
Surface modification of elastomeric stamps for microcontact printing of polar inks. Langmuir (2007) 0.75
Phase transfer of CdS nanocrystals mediated by heptamine β-cyclodextrin. Langmuir (2012) 0.75
Transcranial Motor-Evoked Potentials Are More Readily Acquired Than Somatosensory-Evoked Potentials in Children Younger Than 6 Years. Anesth Analg (2016) 0.75
Evaluation of autoimmunity to transaldolase in multiple sclerosis. Methods Mol Med (2004) 0.75
Nonsurgical carotid revascularization. Cardiol Rev (2005) 0.75
Phenytoin Induced Chorea: A Case Report. Am J Ther (2017) 0.75
Importance of Medication Reconciliation: Tizanidine-Induced Hepatitis. Am J Ther (2017) 0.75
Palpable purpura, polyarthritis and abdominal pain. Med J Aust (2004) 0.75
Computational methods for functional site identification suggest a substrate access channel in transaldolase. Genome Inform (2006) 0.75